The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer
- 19 June 2014
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 40 (8) , 934-941
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approachInvestigational New Drugs, 2013
- VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patientsAngiogenesis, 2012
- Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment EfficacyClinical Cancer Research, 2010
- The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal CancerThe Oncologist, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic FactorsClinical Cancer Research, 2008
- Tumor Angiogenesis: Initiation and Targeting - Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas -Cancer Research and Treatment, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11British Journal of Cancer, 2003
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971